Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	47.71	33.79	43.05	65.47	112.35	4.21
Short-Term Investments	154.9	35.71	24.69	17.38	-	-
Cash & Short-Term Investments	202.61	69.5	67.74	82.85	112.35	4.21
Cash Growth	311.33%	2.60%	-18.24%	-26.26%	2566.65%	30.96%
Accounts Receivable	10.98	10.18	16.12	7.19	1.42	2.44
Other Receivables	7.28	0.33	1.26	1.11	0.11	0.14
Receivables	18.27	10.51	17.38	8.3	1.53	2.58
Inventory	1.11	1.97	-	-	-	-
Prepaid Expenses	4.35	4.05	1.82	1.69	0.89	0.66
Restricted Cash	-	-	-	-	-	0.11
Other Current Assets	-	-	-	-	0.29	0.83
Total Current Assets	226.34	86.03	86.94	92.83	115.06	8.38
Property, Plant & Equipment	2.1	1.01	1.53	1.78	2.03	2.39
Long-Term Investments	15.09	6.01	-	20	15.42	-
Goodwill	4.7	4.7	4.7	-	-	-
Other Intangible Assets	7.05	68.99	69.23	-	-	-
Long-Term Accounts Receivable	-	-	-	-	-	0.4
Other Long-Term Assets	1	11.38	9.94	0.72	0.44	0.04
Total Assets	256.28	178.13	172.33	115.34	132.94	11.21
Accounts Payable	15.84	13.08	13.99	3.61	0.52	1.17
Accrued Expenses	5.6	17.37	18.97	7.21	2.52	5.47
Short-Term Debt	-	-	37.7	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.39
Current Portion of Leases	0.53	0.42	0.54	0.49	0.37	0.5
Other Current Liabilities	6.87	3.2	2.52	0.71	0.82	-
Total Current Liabilities	28.83	34.07	73.72	12.02	4.23	7.54
Long-Term Debt	60.69	59.5	5.07	12.8	-	68.05
Long-Term Leases	1.06	0.37	0.46	0.84	1.24	1.61
Other Long-Term Liabilities	48.46	44.52	31.22	14.55	0.36	0.43
Total Liabilities	139.05	138.46	110.46	40.22	5.82	77.62
Common Stock	0.01	0.01	0	0	0	-
Additional Paid-In Capital	564.32	555.3	472.66	436.27	396.96	192.06
Retained Earnings	-433.68	-505.29	-399.78	-353.73	-267.03	-258.47
Treasury Stock	-10.98	-10.98	-10.98	-7.54	-2.81	-
Comprehensive Income & Other	-2.43	0.63	-0.04	0.11	-	-
Total Common Equity	117.23	39.67	61.86	75.12	127.12	-66.41
Shareholders' Equity	117.23	39.67	61.86	75.12	127.12	-66.41
Total Liabilities & Equity	256.28	178.13	172.33	115.34	132.94	11.21
Total Debt	62.28	60.3	43.77	14.13	1.61	70.55
Net Cash (Debt)	140.34	9.2	23.97	68.72	110.74	-66.33
Net Cash Growth	-	-61.62%	-65.11%	-37.95%	-	-
Net Cash Per Share	2.67	0.20	0.68	1.99	3.72	-16.66
Filing Date Shares Outstanding	56.14	54.12	41.85	34.54	34.42	28.38
Total Common Shares Outstanding	55.08	53.67	41.53	34.54	35.01	4.54
Working Capital	197.51	51.96	13.22	80.81	110.83	0.85
Book Value Per Share	2.13	0.74	1.49	2.17	3.63	-14.64
Tangible Book Value	105.48	-34.03	-12.06	75.12	127.12	-66.41
Tangible Book Value Per Share	1.91	-0.63	-0.29	2.17	3.63	-14.64
Machinery	-	1.36	1.51	1.28	1.05	1.01
Leasehold Improvements	-	0.71	0.71	0.71	0.72	0.72

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q